New hope for deadly pancreatic cancer: immunotherapy trial seeks better treatments
NCT ID NCT04787991
Summary
This early-stage trial tested whether adding immunotherapy drugs to standard chemotherapy could help people with newly diagnosed metastatic pancreatic cancer. The study enrolled 45 participants who hadn't received prior treatment for their advanced cancer. Researchers tested different drug combinations to evaluate safety and see if tumors responded better than with chemotherapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Stanford University
Stanford, California, 94305, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.